Biocon vs Biocon

Centrion of curia, which has been right at the forefront of this biosimilar evolution, they have somewhere around 18 to 20 billion dollar in valuation. Samting biologic, which also does a lot of manufacturing for other biosimilar companies, they have upwards of forty billion dollars in valuation. In those situations, we can't make a like to like comparison, but they still appears to be not a very inflated one along the same vein kiran also had an interesting nugative information to share. She spoke about house large debt is not looked upon favourably in the farmer space. Most farmer companies are pretty low on detiquity and they're not very highly leveraged.